About: Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID‐19
Creator	Brouns, Steffie Brüggemann, Renée Heijnen, Ron Joosten, Hanneke Linkens, Aimée Magdelijns, Fabienne Spaetgens, Bart Ten Cate, Hugo Ten Cate-Hoek, Arina
Source	Medline; PMC
abstract	BACKGROUND/OBJECTIVES: Nursing home (NH) residents are a vulnerable population, susceptible to respiratory disease outbreaks such as coronavirus disease 2019 (COVID‐19). Poor outcome in COVID‐19 is at least partly attributed to hypercoagulability, resulting in a high incidence of thromboembolic complications. It is unknown whether commonly used antithrombotic therapies may protect the vulnerable NH population with COVID‐19 against mortality. This study aimed to investigate whether the use of oral antithrombotic therapy (OAT) was associated with a lower mortality in NH residents with COVID‐19. DESIGN: A retrospective case‐series SETTING: 14 NH facilities from the NH organization Envida, Maastricht, the Netherlands PARTICIPANTS: 101 NH residents with COVID‐19 were enrolled. MEASUREMENTS: The primary outcome was all‐cause mortality. The association between age, sex, comorbidity, OAT, and mortality was assessed using logistic regression analysis. RESULTS: Overall mortality was 47.5% in NH residents from 14 NH facilities. Age, comorbidity and medication use were comparable among NH residents who survived and who died. OAT was associated with a lower mortality in NH residents with COVID‐19 in the univariable analysis (OR 0.89 95%CI 0.41‐1.95). However, additional adjustments for sex, age and comorbidity, attenuated this difference. Mortality in males was higher compared with female residents (OR 3.96 (95%CI 1.62‐9.65)). Male residents who died were younger compared to female residents (82.2 (SD 6.3) vs. 89.1 years (SD 6.8), p<.001). CONCLUSION: NH residents in the 14 facilities we studied were severely affected by the COVID‐19 pandemic, with a mortality of 47.5%. Male NH residents with COVID‐19 had worse outcomes than females. We did not find evidence for any protection against mortality by OAT, necessitating further research into strategies to mitigate poor outcome of COVID‐19 in vulnerable NH populations. This article is protected by copyright. All rights reserved.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1111/jgs.16664
bibo:pmid	32633418
has license	no-cc
sha1sum (hex)	0714f3278cd3b27f7081e1a9b88eeedb6b402578
schema:url	https://doi.org/10.1111/jgs.16664
resource representing a document's title	Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID‐19
has PubMed Central identifier	PMC7361386
has PubMed identifier	32633418
schema:publication	J Am Geriatr Soc
resource representing a document's body	covid:0714f3278cd3b27f7081e1a9b88eeedb6b402578#body_text
is schema:about of	named entity 'This' named entity 'complications' named entity 'therapies' named entity 'Nursing Home' named entity 'POOR OUTCOME' named entity 'UNKNOWN' named entity 'HYPERCOAGULABILITY' named entity 'CORONAVIRUS DISEASE 2019' named entity 'mortality' named entity 'hypercoagulability' named entity 'therapy' named entity 'oral' named entity 'Antithrombotic' named entity 'Nursing Home' named entity 'COVID-19' named entity 'ICU' named entity 'rRT-PCR' named entity 'LMWH' named entity 'SPSS' named entity 'pharyngeal' named entity 'SARS-CoV2' named entity 'COVID' named entity 'chronic conditions' named entity '3.8' named entity 'statistical power' named entity 'COVID-19' named entity 'odds ratios' named entity 'oral anticoagulants' named entity 'flu season' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'direct oral anticoagulants' named entity 'CCI' named entity 'current literature' named entity 'confounders' named entity 'anticoagulant therapy' named entity 'COVID-19' named entity '8.2' named entity 'rRT-PCR' named entity 'excess mortality' named entity 'antithrombotic' named entity 'COVID-19' named entity 'disease burden' named entity '25.0' named entity 'confidence intervals' named entity 'heparin' named entity 'statistically significant' named entity 'polymerase chain reaction' named entity 'general population' named entity 'vitamin K antagonists' named entity 'CCI' named entity 'COVID' named entity 'comorbidity' named entity 'assay' named entity 'COVID19' named entity 'pulmonary disease' named entity '2.0' named entity 'ageing process' named entity 'COVID' named entity 'residual confounding' named entity 'mortality rate' named entity 'hypertension' named entity 'venous thromboembolic events' named entity 'hypertension' named entity 'odds ratios' named entity 'adjusted odds ratio' named entity 'thromboprophylaxis' named entity 'DOAC' named entity 'respiratory disease' named entity 'headache'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software